Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be presenting at two virtual investor conferences during the month of January 2021 . H.C. Wainwright BioConnect 2021 Virtual Confere
CRANFORD, N.J., Jan. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc.. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be presenting at two virtual investor conferences during the month of January 2021. H.C. Wainwright BioConnect 2021 Virtual Conference – January 11 – 14, 2021 MoneyShow Accredited Investors Virtual Expo – January 26 – 28, 2021 “We have exciting developments to discuss at our January conferences and look forward to greeting investors virtually,” said Mr. Myron Holubiak. “From our NoveCite subsidiary, interim data from a proof-of-concept large animal study of induced mesenchymal stem cell (“i-MSC”) therapy in an in vivo model of Acute Respiratory Distress Syndrome (“ARDS”) shows improvement in critical parameters, such as improved oxygenation, less systemic shock, and reduced lung injury, compared to the control group. For Mino-Lok we recently conducted a series of webinars to provide Phase 3 trial updates and discuss the role Mino-Lok may play in the treatment of Central Line Associated Blood Stream Infections (“CLABSIs”). In spite of the headwinds from the Covid-19 pandemic, we have been able to continue to recruit patients for our pivotal trial. Mino-Lok is nearing completion of its phase 3. Mino-Wrap’s novel approach to reducing post-mastectomy infections associated with the use of a tissue expander is on track in its preclinical stage, and, finally, we expect to file an IND for Halo-Lido in the near term and initiate a Phase 2b trial later this year.” Overview of Proprietary Product Candidates Mino-Lok®: Mino-Lok is a late-stage development product in Phase III trials. Citius has partnered with MD Anderson Cancer Center (MDACC), a world-leading cancer center, to develop Mino-Lok. Mino-Lok has received Qualified Infectious Disease Product (“QIDP”) designation providing fast track status, priority review, and additional market exclusivity. CITI 101 – Mino-Wrap: Mino-Wrap, or CITI 101, is a liquefying gel-based wrap containing minocycline and rifampin designed to provide inflammatory tissue protection and prevent infection and biofilm formation in tissue expanders and breast implants post-mastectomy. In January 2019, Citius signed a definitive license agreement with MDACC to develop and commercialize a novel approach to reducing postoperative infections associated with surgical implants estimated to be 12-14%. CITI-002 – Halo-Lido: Citius is developing a topical formulation of halobetasol, a corticosteroid, and lidocaine to provide anti-inflammatory and anesthetic symptomatic relief to people with hemorrhoids. Citius is advancing its combination therapy for hemorrhoids as being synergistic to its individual components and is pursuing a patent for the new halobetasol-lidocaine formulation. If this formulation is approved by the FDA, Citius would have the only FDA-approved prescription-strength product on the market proven to be safe and effective for the treatment of hemorrhoids. About Citius Pharmaceuticals, Inc. Safe Harbor Contact:
SOURCE Citius Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-SMALL:CTXR |